Compounds with antibacterial activity that enhance DNA cleavage by bacterial DNA topoisomerase I

被引:45
作者
Cheng, Bokun [1 ]
Liu, I-Fen [1 ]
Tse-Dinh, Yuk-Ching [1 ]
机构
[1] New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA
关键词
antibiotics; high throughput screening; Y; pestis;
D O I
10.1093/jac/dkl556
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: DNA topoisomerases utilize a covalent complex formed after DNA cleavage as an intermediate in the interconversion of topological forms via DNA cleavage and religation. Many anticancer and antibacterial therapeutic agents are effective because they stabilize or increase the level of the covalent topoisomerase-DNA complex formed by type IIA or type IB topoisomerases. Our goal is to identify small molecules that can enhance DNA cleavage by type IA DNA topoisomerase. Compounds that act in this mechanism against type IA topoisomerase have not been identified previously and could be leads for development of a new class of antibacterial agents. Methods: High throughput screening was carried out to select small molecules that induce the SOS response of Escherichia coli, overexpressing recombinant Yersinia pestis topoisomerase I. The initial hit compounds were further tested for inhibition of bacterial growth and bacterial topolsomerase I activity. Results: Three compounds with antibacterial activity that enhance the cleavage activity of bacterial topoisomerase I were identified. Conclusions: Small molecules that can enhance the DNA cleavage activity of type IA DNA topoisomerase can be identified and may provide leads for development of novel antibacterial compounds.
引用
收藏
页码:640 / 645
页数:6
相关论文
共 40 条
  • [1] Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde
    Anderson, VE
    Osheroff, N
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2001, 7 (05) : 337 - 353
  • [2] Recognition of specific sequences in DNA by a topoisomerase I inhibitor derived from the antitumor drug rebeccamycin
    Bailly, C
    Colson, P
    Houssier, C
    Rodrigues-Pereira, E
    Prudhomme, M
    Waring, MJ
    [J]. MOLECULAR PHARMACOLOGY, 1998, 53 (01) : 77 - 87
  • [3] Imp/OstA is required for cell envelope biogenesis in Escherichia coli
    Braun, M
    Silhavy, TJ
    [J]. MOLECULAR MICROBIOLOGY, 2002, 45 (05) : 1289 - 1302
  • [4] Multi-resistant Gram-negative bacilli:: from epidemics to endemics
    Cantón, R
    Coque, TM
    Baquero, F
    [J]. CURRENT OPINION IN INFECTIOUS DISEASES, 2003, 16 (04) : 315 - 325
  • [5] Capranico Giovanni, 2004, Current Medicinal Chemistry - Anti-Cancer Agents, V4, P335, DOI 10.2174/1568011043352885
  • [6] Caron PR, 1999, METH MOL B, V94, P279
  • [7] DNA topoisomerases: Structure, function, and mechanism
    Champoux, JJ
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 2001, 70 : 369 - 413
  • [8] Bacterial cell killing mediated by topoisomerase I DNA cleavage activity
    Cheng, B
    Shukla, S
    Vasunilashorn, S
    Mukhopadhyay, S
    Tse-Dinh, YC
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (46) : 38489 - 38495
  • [9] Denny William A, 2004, Expert Opin Emerg Drugs, V9, P105, DOI 10.1517/14728214.9.1.105
  • [10] ESCHERICHIA-COLI DNA TOPOISOMERASE-I MUTANTS HAVE COMPENSATORY MUTATIONS IN DNA GYRASE GENES
    DINARDO, S
    VOELKEL, KA
    STERNGLANZ, R
    REYNOLDS, AE
    WRIGHT, A
    [J]. CELL, 1982, 31 (01) : 43 - 51